Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Smith

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Journal of Virology|May 22, 2002
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccineRama Rao Amara, James M Smith, Silvija I Staprans, et al.
Radiology|March 18, 2020
Patient Exposure from Radiologic and Nuclear Medicine Procedures in the United States: Procedure Volume and Effective Dose for the Period 2006-2016Fred A Mettler, Mahadevappa Mahesh, Mythreyi Bhargavan-Chatfield, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2012
Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaquesJohn A Moss, Amanda M Malone, Thomas J Smith, et al.
Journal of Medicinal Chemistry|April 26, 2021
Fragment-Based Design of a Potent MAT2a Inhibitor and <i>in Vivo</i> Evaluation in an MTAP Null Xenograft ModelClaudia De Fusco, Marianne Schimpl, Ulf Börjesson, et al.
Plos Pathogens|September 23, 2016
Increases in Endogenous or Exogenous Progestins Promote Virus-Target Cell Interactions within the Non-human Primate Female Reproductive TractAnn M Carias, Shannon A Allen, Angela J Fought, et al.
Bioorganic & Medicinal Chemistry|October 22, 2020
Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitorsSébastien L Degorce, Anna Aagaard, Rana Anjum, et al.
Journal of Medicinal Chemistry|May 22, 2026
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical EvaluationJames M Smith, Bernard Barlaam, David Beattie, et al.
Vaccine|May 2, 2002
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccineRama Rao Amara, Francois Villinger, John D Altman, et al.
Journal of Medicinal Chemistry|September 12, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal TumorsJason G Kettle, Rana Anjum, Evan Barry, et al.
Journal of Medicinal Chemistry|April 8, 2015
Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3Scott Boyd, Joanna L Brookfield, Susan E Critchlow, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Journal of Virology|May 22, 2002
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccineRama Rao Amara, James M Smith, Silvija I Staprans, et al.
Radiology|March 18, 2020
Patient Exposure from Radiologic and Nuclear Medicine Procedures in the United States: Procedure Volume and Effective Dose for the Period 2006-2016Fred A Mettler, Mahadevappa Mahesh, Mythreyi Bhargavan-Chatfield, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2012
Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaquesJohn A Moss, Amanda M Malone, Thomas J Smith, et al.
Journal of Medicinal Chemistry|April 26, 2021
Fragment-Based Design of a Potent MAT2a Inhibitor and <i>in Vivo</i> Evaluation in an MTAP Null Xenograft ModelClaudia De Fusco, Marianne Schimpl, Ulf Börjesson, et al.
Plos Pathogens|September 23, 2016
Increases in Endogenous or Exogenous Progestins Promote Virus-Target Cell Interactions within the Non-human Primate Female Reproductive TractAnn M Carias, Shannon A Allen, Angela J Fought, et al.
Bioorganic & Medicinal Chemistry|October 22, 2020
Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitorsSébastien L Degorce, Anna Aagaard, Rana Anjum, et al.
Journal of Medicinal Chemistry|May 22, 2026
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical EvaluationJames M Smith, Bernard Barlaam, David Beattie, et al.
Vaccine|May 2, 2002
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccineRama Rao Amara, Francois Villinger, John D Altman, et al.
Journal of Medicinal Chemistry|September 12, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal TumorsJason G Kettle, Rana Anjum, Evan Barry, et al.
Journal of Medicinal Chemistry|April 8, 2015
Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3Scott Boyd, Joanna L Brookfield, Susan E Critchlow, et al.
Pageof 9